Analyst Price Target is GBX 256
▲ +82.86% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Arix Bioscience in the last 3 months. The average price target is GBX 256, with a high forecast of GBX 256 and a low forecast of GBX 256. The average price target represents a 82.86% upside from the last price of GBX 140.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Arix Bioscience. This rating has held steady since June 2021, when it changed from a Hold consensus rating.
Arix Bioscience plc is a venture capital firm specializing in all stages of growth, seed stage, preclinical and clinical stage assets, startup, early stage, mid venture, late stage, growth capital investments as well as private and public equity. The firm seeks to invest in biotech companies, novel therapeutics, innovative technologies, medical innovation comprising healthcare and life sciences. It seeks to invest globally. The firm employs an evergreen approach to funding. It primarily makes investments from its own balance sheet. The firm prefers to take board seat. The firm exit when the optimum value has been reached. Arix Bioscience plc is formerly known as Perceptive Bioscience Investments Limited. Arix Bioscience plc was founded in 2015 and is based in London, United Kingdom.